Last reviewed · How we verify
Tadalafil- Tablet or Oral suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tadalafil- Tablet or Oral suspension (Tadalafil- Tablet or Oral suspension) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tadalafil- Tablet or Oral suspension TARGET | Tadalafil- Tablet or Oral suspension | Eli Lilly and Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tadalafil- Tablet or Oral suspension CI watch — RSS
- Tadalafil- Tablet or Oral suspension CI watch — Atom
- Tadalafil- Tablet or Oral suspension CI watch — JSON
- Tadalafil- Tablet or Oral suspension alone — RSS
Cite this brief
Drug Landscape (2026). Tadalafil- Tablet or Oral suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/tadalafil-tablet-or-oral-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab